Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation

Condition:   BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA Intervention:   Drug: Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting Sponsors:   Assistance Publique - Hôpitaux de Paris;   AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials